Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 1, 2007, Pages 131-136

  Greenspan, Susan L ^a   Bhattacharya, Rajib K ^e   Sereika, Susan M ^b,c   Brufsky, Adam ^a,d   Vogel, Victor G ^a,b,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; AROMATASE INHIBITOR; OSTEOCALCIN; PLACEBO; PROCOLLAGEN; RISEDRONIC ACID; TAMOXIFEN;

ADULT; ARTHRALGIA; ARTICLE; BONE ATROPHY; BONE DENSITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; FEMALE; FRACTURE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MYALGIA; OSSIFICATION; OSTEOLYSIS; PARTIAL MASTECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 33846049281     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1272     Document Type: Article

References (29)

1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA 2005 Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 34:405-412
2. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687
3. Pfeilschifter J, Diel IJ 2000 Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570-1593
4. del Mastro L, Venturini M, Sertoli MR, Rosso R 1997 Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Br Cancer Res Treat 43:183-190
5. Schilsky RL, Lewis BJ, Sherins RJ, Young RC 1980 Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 93:109-116
6. Bines J, Oleske DM, Cobleigh MA 1996 Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729
7. Shapiro CL, Manola J, LeBoff M 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311
8. Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, LeBoff MS 2005 Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study. Arch Intern Med 165:552-558
9. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A 1997 Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double blind, placebo controlled study. J Clin Oncol 15:955-962
10. Saarto T, Elomaa I 1997 Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347
11. VehmanenL, Saarto T, Risteli J, Risteli L, Blomqvist C, Elomaa I 2004 Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 87:181-188
12. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C 2001 Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients: the effect of adjuvant clodronate treatment. Eur J Cancer 37:2373-2378
13. Powles TJ, McCloskey E, Patterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J 1998 Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704-708
14. El-Hajj Fuleihan G, Salamoun M, Mourad YA, Chelhal A, Salem Z, Mahfoud Z, Shamseddine A 2005 Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer. J Clin Endocrinol Metab 90:3209-3214
15. Dawson-Hughes B, Jacques P, Shipp C 1987 Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr 46:685-687
16. Towers AL, Clay CA, Sereika SM, McIntosh I, Greenspan SL 2005 Skeletal integrity in patients with nail patella syndrome. J Clin Endocrinol Metab 90:1961-1965
17. Brown H, Prescott R 1999 Applied mixed models in medicine. Chichester, UK: John Wiley, Sons
18. Diggle PJ, Liang KY, Zeger SL 1995 Analysis of longitudinal data. New York: Oxford University Press
19. Kanis JA, for the WHO Study Group 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368-381
20. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke R, Thompson DE, de Papp AE, for the Fosamax Actonel Comparison Trial Investigators 2005 Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141-151
21. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Delmas PD 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531-1538
22. U.S. Department of Health and Human Services 2004 Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General
23. The ATAC Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the trial. Lancet 359:2131-2139
24. Eastell R, Hannon R 2005 Long-term effects of aromatase inhibitors on bone. J Steroid Biochem Mol Biol 95:151-154
25. The Breast International Group (BIG) 1-98 Collaborative Group 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757
26. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
27. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LG, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Intergroup Exemestane Study 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
28. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P 2005 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147
29. Winer EP, Hudis C, Burstein HJ, Wolff AC, Prtchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR 2005 American Society of the Clinical Oncology Technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 23:619-629